Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
NUVL reported proposed and recent sales of common stock by an affiliate. The filing lists proposed sales tied to option exercises and restricted stock units, and discloses two completed sales by Henry E. Pelish on 01/05/2026 (2,496 shares for $242,905.02) and 01/06/2026 (2,664 shares for $258,847.87). The schedule also shows prior and planned issuances from option exercises and RSU vesting with quantities listed by grant date.
Nuvalent, Inc. President and CEO James Richard Porter exercised stock options for 30,000 shares of Class A common stock at an exercise price of $27.85 per share. These options were part of a grant vesting monthly over four years from January 6, 2023.
On the same date, he sold 30,000 shares of Class A common stock in open-market transactions at weighted average prices of about $98.59, $99.29 and $100.19, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025. Following these transactions, he directly holds 324,879 shares of Nuvalent Class A common stock.
Nuvalent, Inc.’s Chief Development Officer Darlene Noci reported option exercises and share sales. On February 26, 2026, she exercised stock options for 5,500 shares of Class A common stock and acquired those shares via derivative conversion.
On the same date, she sold a total of 5,500 Class A common shares in open-market transactions at weighted average prices between $102.04 and $104.41 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she held 58,117 Class A common shares directly.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options for 5,500 shares of Class A common stock on February 26, 2026, converting a derivative security into common stock at an exercise price of approximately $6.89 per share. On the same date, she sold a total of 5,500 shares of Class A common stock in open-market transactions at weighted average prices ranging from $101.96 to $103.95, pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 59,634 shares of Class A common stock and 89,108 derivative securities.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on precisely targeted kinase inhibitors for cancer, with no approved products or revenue and a history of net losses. Its strategy centers on overcoming resistance, off‑target toxicities and limited brain penetrance seen with current therapies.
Lead drug zidesamtinib (NVL‑520) targets ROS1‑positive non-small cell lung cancer (NSCLC). A New Drug Application has been accepted by the FDA for adults with locally advanced or metastatic ROS1‑positive NSCLC previously treated with at least one ROS1 TKI, with a PDUFA target action date of September 18, 2026. Nuvalent also plans to seek a label expansion in TKI‑naïve patients using data from the ongoing ARROS‑1 Phase 2 trial.
Neladalkib (NVL‑655), an ALK‑selective, brain‑penetrant inhibitor for ALK‑positive NSCLC, has FDA Breakthrough Therapy designation. Positive topline data in TKI pre‑treated patients were reported from the ALKOVE‑1 Phase 1/2 trial, and Nuvalent intends to submit an NDA in the first half of 2026. The ALKAZAR Phase 3 trial is comparing neladalkib to alectinib in TKI‑naïve ALK‑positive NSCLC.
NVL‑330, a HER2‑selective, brain‑penetrant inhibitor for HER2‑altered NSCLC, is in the HEROEX‑1 Phase 1a/1b trial, supported by preclinical data showing broad HER2 activity and CNS penetration. Under its OnTarget 2026 plan, Nuvalent aims for its first potential U.S. commercial launch of zidesamtinib in 2026, pending FDA review, an NDA submission for neladalkib, continued development of NVL‑330, and disclosure of a new development candidate by year-end 2026.
Nuvalent, Inc. reported a larger net loss while advancing its lung cancer drug pipeline. For the fourth quarter of 2025, net loss was $118.7 million, and for the full year 2025 net loss was $425.4 million, driven by research and development and growing administrative expenses.
Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025, and the company expects its cash runway to extend into 2029. The FDA accepted the NDA for zidesamtinib in ROS1-positive NSCLC with a PDUFA target action date of September 18, 2026, and Nuvalent plans an NDA for neladalkib in ALK-positive NSCLC in the first half of 2026.
Nuvalent, Inc. insider-related trust plans modest stock sale under Rule 144. A Form 144 notice reports that the Matthew Shair 2021 Irrevocable Trust intends to sell 1,650 shares of Nuvalent Class A common stock through J.P. Morgan Securities on Nasdaq, with an aggregate market value of 166,125. The notice states that 67,271,461 Class A shares were outstanding, providing context for the planned sale’s relative size. The shares to be sold were originally acquired by grant and transferred to the trust on 07/13/2021. The filing also lists several prior sales by the same trust over the past three months.
Nuvalent, Inc. insider-related trust plans stock sale under Rule 144. A holder of Nuvalent Class A common stock filed notice to sell 5,850 shares through J.P. Morgan Securities LLC, with an aggregate market value of 588,990, on or around 02/17/2026 on Nasdaq.
The securities were originally acquired as founder shares from the issuer on 02/17/2017. The filing also lists recent sales by the same trust, including 5,850 Class A shares sold on 11/24/2025 for gross proceeds of 639,807 and additional smaller transactions over the following months.
Nuvalent, Inc. received an amended Schedule 13G/A showing that investment entities affiliated with Deerfield report significant beneficial ownership of its Class A common stock. Deerfield Management Company, L.P. and James E. Flynn each report beneficial ownership of 22,852,280 shares, or 24.21% of the Class A shares outstanding.
This position includes 17,248,450 existing Class A shares, 5,435,254 Class A shares issuable upon conversion of Class B shares, and 168,576 Class A shares underlying options and restricted stock units held by Nuvalent employees for Deerfield’s benefit. Several related Deerfield funds individually report 11.56% or 0.91% stakes.
The Class B shares are subject to an Ownership Cap that generally limits conversions so that the holder and its affiliates do not exceed 4.9% of Nuvalent’s outstanding Class A common stock upon conversion.